Researchers analyzed how healthcare disparities in diverse groups affect multiple myeloma care, leading to more complications post-multiple therapies. Access to treatments for initial relapses is uneven. Researchers conclude that clinicians need to discuss treatments fairly and support disadvantaged patients intensively. Regular disease monitoring and ensuring all patients, including those with relapsed myeloma, have access to advanced treatments like belantamab and selinexor are key. Early supportive care is crucial for side effect management and better patient outcomes.

Reference: Steinbach M, Colson K, Faiman B. A Focus on Special Populations in Relapsed Multiple Myeloma. J Adv Pract Oncol. 2022 Jul;13(Suppl 4):23-30. doi: 10.6004/jadpro.2022.13.5.12. Epub 2022 Jul 28. PMID: 35937464; PMCID: PMC9342922. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342922/